证券记录 · 已归档季度
COLL
Collegium Pharmaceutical, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
19被追踪持有人
+2Δ持有人
14.79M持有股份
$517.39M报告持仓市值
+2新建仓位
−0清仓
动量输入（同类管理人）：
持有人广度 +11.8% ·
股份流向 +3.1% ·
净新建仓位 +10.5%
· 公式
广泛增持：持股数量上升，持有人数量增加
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 96 | +3 | 27.22M | $985.07M | +8 | −7 |
| Q1 2026 | 98 | -1 | 28.14M | $930.88M | +7 | −9 |
| Q4 2025 | 100 | 0 | 26.92M | $1.25B | +1 | n/a |
| Q3 2025 | 19 | +2 | 14.79M | $517.39M | +2 | n/a |
| Q2 2025 | 14 | +1 | 12.36M | $365.37M | +1 | n/a |
| Q1 2025 | 10 | -1 | 5.48M | $163.49M | n/a | −1 |
| Q4 2024 | 11 | -1 | 5.00M | $143.28M | n/a | −1 |
| Q3 2024 | 11 | -1 | 3.77M | $145.78M | n/a | −1 |
| Q2 2024 | 12 | n/a | 3.67M | $118.10M | n/a | n/a |
持有人 · Q3 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (被动) | 5.18M | -3.1% | $181.18M | 0.0% | ▼ Trim | 2 | SEC ↗ ×15 |
| 2 | The Vanguard Group ✦ (被动) | 2.23M | -1.0% | $77.90M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 3 | Renaissance Technologies ✦ | 1.60M | +5.1% | $55.96M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 4 | State Street Global Advisors ✦ (被动) | 1.29M | -4.5% | $45.27M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | Geode Capital Management ✦ (被动) | 836.38K | +7.2% | $29.27M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 6 | Goldman Sachs Group ✦ | 802.23K | n/a | $28.07M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 7 | Morgan Stanley ✦ | 767.42K | n/a | $26.85M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 8 | JPMorgan Chase ✦ | 423.51K | n/a | $14.82M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 9 | D. E. Shaw & Co. ✦ | 389.77K | +91.1% | $13.64M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 10 | Marshall Wace ✦ | 279.01K | +104.1% | $9.76M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 11 | Two Sigma Investments ✦ | 269.32K | +897.2% | $9.42M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 253.50K | +5.6% | $8.87M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 13 | Wellington Management ✦ | 122.98K | +24.3% | $4.30M | 0.0% | ▲ Add | 6 | SEC ↗ ×5 |
| 14 | Millennium Management ✦ | 122.19K | -45.5% | $4.28M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 87.18K | -3.5% | $3.05M | 0.0% | ▼ Trim | 6 | SEC ↗ ×5 |
| 16 | Fidelity (FMR) ✦ | 58.86K | +12.0% | $2.06M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 17 | T. Rowe Price ✦ | 34.97K | -3.6% | $1.22M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 18 | Arrowstreet Capital ✦ | 33.71K | 新增 | $1.18M | 0.0% | New | 1 | SEC ↗ |
| 19 | Gotham Asset Management ✦ | 8.19K | 新增 | $286,393 | 0.0% | New | 1 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| Arrowstreet Capital | $1.18M | 0.0% |
| Gotham Asset Management | $286,393 | 0.0% |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 264 持有人, 37.57M 股份, $1.22B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q3 2025 ·
方法论 ·
通过API获取此数据